Sanofi公布新一代Lantus三期研究数据

2013-07-03 yangtao 生物谷

Sanofi公司公布了新一代Lantus的三期研究数据。Lantus是Sanofi公司销售最好的一种口服糖尿病药物。作为这种药物的新一代产品--U300,研究数据表明其比Lantus更安全。在美国糖尿病学会的年会上,Sanofi公司公布了这一研究成果。 Lantus是如今糖尿病市场上销售最好的药物,然而其专利许可将在2015年到期,U300的出现可能帮助Sanofi公司继续保持在该市场的龙头

Sanofi公司公布了新一代Lantus的三期研究数据。Lantus是Sanofi公司销售最好的一种口服糖尿病药物。作为这种药物的新一代产品--U300,研究数据表明其比Lantus更安全。在美国糖尿病学会的年会上,Sanofi公司公布了这一研究成果。

Lantus是如今糖尿病市场上销售最好的药物,然而其专利许可将在2015年到期,U300的出现可能帮助Sanofi公司继续保持在该市场的龙头位置

详细英文报道:

CHICAGO--Sanofi ($SNY) has provided the first glimpse at Phase III data for new insulin glargine, which is a next-generation version of its top-selling diabetes drug Lantus. Hoping to ease regulators' concerns about the potential side effects of a new diabetes drug, the late-stage trial shows that the next-gen drug could be safer than Lantus in patients with Type 2 diabetes.

In the debut of the study data here at the annual meeting of the American Diabetes Association, Sanofi said that the experimental insulin, dubbed U300, showed equal ability to keep blood sugar levels under control as Lantus, meeting the study's main goal of noninferiority to the marketed drug.

A key secondary endpoint focused on nighttime low blood sugar, or nocturnal hypoglycemia, which can be deadly in severe cases. Sanofi showed positive data on this score, with fewer cases of low blood sugar at night for patients on U300 compared with Lantus. During months three to 6 of the study, 36.1% of patients on U300 compared with 46% on Lantus suffered from nocturnal hypoglycemia, Sanofi said.

"Whatever improvements we can do in any therapy that reduces hypoglycemia is a good thing," said Dr. Robert Cuddihy, Sanofi's vice president and medical diabetes head, in an interview with FierceBiotech. Hypoglycemia is particularly scary for patients when they are asleep, he said, because their symptoms are more difficult to notice.

The Phase III results come from Sanofi's Edition I study, which is the first of four late-stage trials that the company plans to report this year for U300. Also, top-line data from the Edition II study have confirmed the equal blood-sugar control and reduction in nocturnal hypoglycemia seen in the first study in the late-stage program. Sanofi aims to file for U.S. and European approvals of U300 in the first half of 2014.

Sanofi has a lot riding on showing that U300 is an improvement. The French drug giant's major competitors such as Novo Nordisk ($NVO) and Eli Lilly ($LLY) have been advancing their own long-lasting insulin products, including Lilly's own copycat version of Lantus, in late-stage clinical trials. Novo has also talked up the reductions in nighttime hypoglycemia for patients on its long-acting insulin called Tresiba, which is approved in Europe.

Lantus, which generated 2012 sales of €4.96 billion ($6.5 billion), is the most prescribed long-acting insulin on the market. Yet Lantus loses patent exclusivity in February 2015. And U300 gives Sanofi a chance to stay No. 1 in the market. Sanofi caught a break after the FDA denied approval of Novo's Tresiba, seeking additional clinical data that should significantly delay Novo in delivering its rival therapy onto the U.S market.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1989213, encodeId=0a03198921382, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Mon Aug 19 23:03:00 CST 2013, time=2013-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656437, encodeId=9c80165643e8f, content=<a href='/topic/show?id=579a158e5a9' target=_blank style='color:#2F92EE;'>#Sanofi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15875, encryptionId=579a158e5a9, topicName=Sanofi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ece524837860, createdName=lq0309, createdTime=Tue Sep 10 12:03:00 CST 2013, time=2013-09-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1989213, encodeId=0a03198921382, content=<a href='/topic/show?id=496ce340173' target=_blank style='color:#2F92EE;'>#研究数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73401, encryptionId=496ce340173, topicName=研究数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Mon Aug 19 23:03:00 CST 2013, time=2013-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656437, encodeId=9c80165643e8f, content=<a href='/topic/show?id=579a158e5a9' target=_blank style='color:#2F92EE;'>#Sanofi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15875, encryptionId=579a158e5a9, topicName=Sanofi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ece524837860, createdName=lq0309, createdTime=Tue Sep 10 12:03:00 CST 2013, time=2013-09-10, status=1, ipAttribution=)]
    2013-09-10 lq0309